Summers et al. — Protein Dose and Muscle Protein Synthesis in Critical Illness

1. Publication

• Title: Increasing protein dose does not further augment muscle protein synthesis in critical illness: a randomized, controlled clinical trial
• Acronym: None assigned
• Year & Journal: American Journal of Respiratory and Critical Care Medicine, 2026;212(5):964-971
• Citation: Summers MJ, Kouw IWK, Asser IE, et al. Increasing protein dose does not further augment muscle protein synthesis in critical illness: a randomized, controlled clinical trial. Am J Respir Crit Care Med. 2026;212(5):964-971. doi:10.1093/ajrccm/aamag086

2. Context & Rationale

Background: Critical illness impairs the muscle protein synthetic response to protein administration ("anabolic resistance"). Whether increasing the protein dose can overcome this resistance was unknown, despite ongoing debate (e.g., EFFORT Protein, PRECISe, TARGET Protein trials) about optimal ICU protein dosing at the clinical-outcome level. This trial addressed the underlying physiological/mechanistic question directly.

Research Question/Hypothesis: In mechanically ventilated critically ill patients, does a single intraduodenal bolus of 40g protein produce greater postprandial muscle protein synthesis rates than 20g protein?

Why This Matters: This mechanistic trial addresses whether the biological rationale underlying higher-protein-dose clinical trials (which have generally shown no clinical benefit, e.g., EFFORT Protein, PRECISe) is even physiologically sound — i.e., does more protein actually synthesize more muscle in ICU patients, independent of downstream clinical outcomes.

3. Design & Methods

• Study Type: Randomized, controlled, mechanistic clinical trial using stable isotope tracer methodology
• Setting & Centers: Not fully detailed in available trial text (multi-author, multi-institutional collaboration spanning Australia and the Netherlands based on author affiliations)
• Population:
• Inclusion: Mechanically ventilated critically ill patients
• Exclusions: Not detailed in available trial text
• Intervention: Single intraduodenal bolus of 40g protein
• Comparator: Single intraduodenal bolus of 20g protein
• Randomization: Not detailed in available trial text (sample size not accessible)
• Blinding: Not detailed in available trial text
• Statistical Power & Follow-Up: Primary outcome: postprandial muscle protein synthesis rates (measured via stable isotope tracer methodology, the gold-standard technique for directly quantifying muscle protein synthesis).

4. Key Results

Note on data completeness: This is a mechanistic/physiological trial with a technically complex primary outcome (stable isotope-derived muscle protein synthesis rate); the exact quantitative results (rates, statistical comparison, sample size) were not available in the accessible source text used for this summary. The paper's title itself states the core finding unambiguously: increasing protein dose did not further augment muscle protein synthesis in this critically ill population.

5. Internal Validity Assessment

• Randomization & Allocation: Described as randomized and controlled; specific concealment/randomization mechanics not detailed in available trial text.
• Protocol Adherence & Separation: A single intraduodenal bolus design ensures precise, verified dose delivery (bypassing potential confounding from variable oral/enteral intake or absorption uncertainty) — a methodological strength for this type of mechanistic trial.
• Blinding & Detection Bias: Not detailed in available trial text; stable isotope tracer methodology for measuring protein synthesis is an objective, laboratory-based technique less susceptible to observer bias regardless of blinding status.
• Missing Data & Sensitivity Analyses: Not detailed in available trial text.
• Overall Internal Validity Conclusion: Indeterminate for this summary given incomplete access to sample size, randomization details, and exact statistical results; however, the intraduodenal bolus delivery method and stable isotope tracer primary outcome are recognized as methodologically rigorous, gold-standard techniques for this specific mechanistic research question.

6. External Validity Assessment

• Population Representativeness: Mechanically ventilated critically ill patients — a relevant population for informing ICU nutrition protocols, though the mechanistic (single-bolus, tracer-based) design is inherently a controlled physiological experiment rather than a real-world feeding protocol.
• Practice Context: The intraduodenal bolus methodology requires specialized research infrastructure (stable isotope tracers, specific delivery routes) not part of routine clinical care — this trial informs the physiological rationale behind protein-dosing guidelines rather than directly testing a bedside-deployable protocol.
• Overall External Validity Conclusion: Moderate for informing the biological plausibility of protein-dosing strategies in mechanically ventilated ICU patients; the mechanistic design means findings should be interpreted alongside (not as a substitute for) large pragmatic clinical-outcome trials (EFFORT Protein, PRECISe, TARGET Protein).

7. Strengths & Limitations

Strengths:

• Uses gold-standard stable isotope tracer methodology to directly measure the mechanistic outcome (muscle protein synthesis) rather than relying on downstream clinical proxies
• Directly addresses the biological plausibility question underlying a series of large, clinically null protein-dosing RCTs (EFFORT Protein, PRECISe)
• Controlled intraduodenal bolus delivery ensures precise dosing

Limitations:

• Mechanistic trial with a single-bolus design does not directly test sustained, real-world feeding protocols
• Exact sample size, statistical results, and population details not accessible for this summary
• Findings address a physiological endpoint, not patient-centered clinical outcomes

8. Interpretation & Practice Impact

• Clinical Implications: This mechanistic finding is consistent with (and helps explain) the pattern of null clinical results from large protein-dosing RCTs in critical illness (EFFORT Protein: no mortality benefit; PRECISe: no functional recovery benefit) — if higher protein doses don't even produce more muscle protein synthesis at the physiological level, it is unsurprising that they fail to improve downstream clinical outcomes.
• Mechanistic Coherence: Supports the concept of a "ceiling" or saturation point in anabolic resistance during critical illness, beyond which additional protein substrate does not translate into additional synthetic response — a genuinely important mechanistic insight for the field's understanding of ICU-acquired weakness pathophysiology.
• Systems-Level Takeaway: Argues against simply escalating protein dose as a strategy to overcome ICU-related muscle wasting; future research may need to target the anabolic resistance mechanism itself (e.g., exercise, anti-inflammatory strategies) rather than substrate delivery alone.

9. Controversies & Subsequent Evidence

• Editorial Commentary/Debates: This trial adds mechanistic weight to the ongoing debate in ICU nutrition about why large protein-dosing RCTs have consistently failed to show clinical benefit despite strong physiological rationale — it suggests the rationale itself ("more protein dose → more muscle synthesis → better outcomes") may break down at the very first mechanistic step.
• Guideline Integration: Contributes to a broader reassessment of ICU nutrition guidelines' historical emphasis on higher protein targets; recent narrative reviews (e.g., "Nutrition support in the ICU: current evidence and evolving standards," Intensive Care Med 2026) note that increasing protein delivery has not consistently improved survival or functional recovery and may even be harmful in specific subgroups (e.g., AKI).

10. Summary & Executive Takeaway

Summary: This mechanistic RCT compared a single 40g versus 20g intraduodenal protein bolus in mechanically ventilated critically ill patients, using stable isotope tracer methodology to measure postprandial muscle protein synthesis rates. Per the study's own title and conclusion, the higher protein dose did not further augment muscle protein synthesis.

Overall Takeaway: This physiological trial provides a mechanistic explanation for why large clinical protein-dosing trials in critical illness (EFFORT Protein, PRECISe) have found no benefit from higher protein targets — anabolic resistance in critical illness appears to limit the muscle synthetic response even when substrate (protein) supply is increased, suggesting future strategies to address ICU-acquired weakness may need to target the resistance mechanism itself rather than simply increasing protein dose.

11. Bibliography

• Heyland DK, Patel J, Compher C, et al. EFFORT Protein trial. Lancet. 2023;401(10376):568-576.
• Bels JLM, Thiessen S, Van Gassel RJJ, et al. PRECISe trial. Lancet. 2024;404:659-669.
• Nutrition support in the ICU: current evidence and evolving standards [review]. Intensive Care Med. 2026.